Serological correlates of immune protection conferred by Chikungunya virus infection

Sheela, P.; Sumathy, K.

doi:10.4149/av_2013_04_471

Cited by 4 publications

(3 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…To date, however, no CHIKV vaccine has been licensed, although a variety of strategies are being evaluated [8][9][10][11][12][13]. Importantly, anti-CHIKV neutralizing antibody titers may be a protective immune correlate [14][15][16]. Passive immunotherapy has been an important short-term intervention against several infectious diseases, including monoclonal antibody (mAb) prophylaxis against respiratory syncytial virus [17].…”

mentioning

confidence: 99%

Rapid and Long-Term Immunity Elicited by DNA-Encoded Antibody Prophylaxis and DNA Vaccination Against Chikungunya Virus

et al. 2016

View full text Add to dashboard Cite

show abstract

mentioning

confidence: 99%

Rapid and Long-Term Immunity Elicited by DNA-Encoded Antibody Prophylaxis and DNA Vaccination Against Chikungunya Virus

et al. 2016

View full text Add to dashboard Cite

show abstract

“…Sumathy from BBIL looked at evolutionary dynamics and serotype analyses [ 218 , 219 ]. Based on the ECSA strain, they developed a pure, inactivated CHIKV immunogenic formulation (BBV87) that may be used as a vaccine to prevent viral infection [ 220 , 221 ].…”

Section: Chikv Research: Indian Scenariomentioning

confidence: 99%

An Overview of Indian Biomedical Research on the Chikungunya Virus with Particular Reference to Its Vaccine, an Unmet Medical Need

et al. 2023

View full text Add to dashboard Cite

Chikungunya virus (CHIKV) is an infectious agent spread by mosquitos, that has engendered endemic or epidemic outbreaks of Chikungunya fever (CHIKF) in Africa, South-East Asia, America, and a few European countries. Like most tropical infections, CHIKV is frequently misdiagnosed, underreported, and underestimated; it primarily affects areas with limited resources, like developing nations. Due to its high transmission rate and lack of a preventive vaccine or effective treatments, this virus poses a serious threat to humanity. After a 32-year hiatus, CHIKV reemerged as the most significant epidemic ever reported, in India in 2006. Since then, CHIKV-related research was begun in India, and up to now, more than 800 peer-reviewed research papers have been published by Indian researchers and medical practitioners. This review gives an overview of the outbreak history and CHIKV-related research in India, to favor novel high-quality research works intending to promote effective treatment and preventive strategies, including vaccine development, against CHIKV infection.

show abstract

“…Antibodies derived from natural infection are believed to provide protection against future infection, and humoral immunity has been shown to protect against viremia in animal models. 25 A virus-like particle (VLP) vaccine candidate has been shown to protect nonhuman primates from infection and recently completed Phase I clinical trials. 26 Antibody development elicited by the vaccine lasted for 6 months, and concentrations at 4 weeks were similar to antibody concentrations in those with natural infection.…”

Section: Impact and Preventionmentioning

confidence: 99%

That Which Bends Up: A Case Report and Literature Review of Chikungunya Virus

et al. 2015

View full text Add to dashboard Cite

Serological correlates of immune protection conferred by Chikungunya virus infection

Cited by 4 publications

References 12 publications

Rapid and Long-Term Immunity Elicited by DNA-Encoded Antibody Prophylaxis and DNA Vaccination Against Chikungunya Virus

Rapid and Long-Term Immunity Elicited by DNA-Encoded Antibody Prophylaxis and DNA Vaccination Against Chikungunya Virus

An Overview of Indian Biomedical Research on the Chikungunya Virus with Particular Reference to Its Vaccine, an Unmet Medical Need

That Which Bends Up: A Case Report and Literature Review of Chikungunya Virus

Contact Info

Product

Resources

About